Matica Bio Secures GMP Manufacturing Deal with Treovir for G207 Therapy

• Matica Bio has partnered with Treovir to advance G207 oncolytic therapy for paediatric brain tumours.

• Matica Bio will provide GMP manufacturing and process optimisation for the Phase 2 clinical trial.

Matica Biotechnology (Matica Bio), a contract development and manufacturing organisation (CDMO) specialising in viral vector development, has announced a partnership with Treovir to address critical gaps in paediatric cancer care. Matica Bio will provide GMP manufacturing for clinical supplies of G207, Treovir’s oncolytic therapy for glioblastoma and other childhood brain tumours, which is currently in Phase 2 clinical trials.

Treovir’s CEO, Michael Christini, highlighted the importance of the collaboration, stating, “Finding a CDMO partner who truly understands our mission and works alongside us as an extension of our team is essential for successful drug development.”

Paul Kim, CEO of Matica Bio, emphasised the company’s commitment to paediatric healthcare, saying, “Pediatric rare diseases represent an area of critical need, and Matica Bio is proud to contribute to the mission of improving the lives of these children.”

This partnership aims to optimise the manufacturing process and accelerate the development of life-saving therapies for critically underserved patient populations. Both companies share a dedication to advancing healthcare solutions for children with rare and challenging conditions.